Telapristone Acetate

Phase 2Small molecule

RRepros Therapeutics Inc.

Telapristone Acetate is one of 89 small molecule programs targeting Mastectomy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Uterine FibroidActive, not recruiting

Breast CancerActive, not recruiting

EndometriosisActive, not recruiting

Uterine FibroidPhase 2

Active, not recruiting

Breast CancerPhase 2

Active, not recruiting

EndometriosisPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Telapristone Acetate

RRepros Therapeutics Inc.

Phase 2

1 3

Lexiscan

Astellas

Preclinical

1 4

Adenocard

Astellas

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

Spravato

WWim Janssens

Preclinical

2 7

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Uterine Fibroid3 trials

Safety and Efficacy of Telapristone Acetate (Proellex®) Administered Vaginally for the Treatment of Uterine Fibroids

Completed·RRepros Therapeutics Inc.·Phase 2·NCT02323646·42 enrolled

A Multi-Center, Parallel Design, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of 6 and 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Completed·RRepros Therapeutics Inc.·Phase 2·NCT02301897·43 enrolled

An Extension Study of 12 mg Proellex® (Telapristone Acetate) Administered Orally in the Treatment of Premenopausal Women With Confirmed Symptomatic Uterine Fibroids

Terminated·RRepros Therapeutics Inc.·Phase 2·NCT02811159·20 enrolled

Endometriosis1 trial

Safety and Efficacy of Telapristone Acetate (Proellex®) in the Treatment of Pre-Menopausal Women With Confirmed, Symptomatic Endometriosis

Completed·RRepros Therapeutics Inc.·Phase 2·NCT01728454·60 enrolled

Breast Cancer1 trial

Oral CDB-4124 vs. Placebo in Stage I-II Primary Breast Cancer

Unknown status·NNorthwestern University·Phase 2·NCT01800422·50 enrolled

Oral1 trial

Comparison of Two Formulations of Proellex for Oral Administration

Completed·RRepros Therapeutics Inc.·Phase 1·NCT02141061·12 enrolled

Mastectomy1 trial

Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

Completed·NNorthwestern University·Phase 2·NCT02314156·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Telapristone Acetate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Telapristone Acetate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Telapristone Acetate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Repros Therapeutics Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RRepros Therapeutics Inc.

Telapristone Acetate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Uterine Fibroid3 trials

Endometriosis1 trial

Breast Cancer1 trial

Oral1 trial

Mastectomy1 trial

References

Drug Info

Quick Facts

Related News